Cover Image

Update breast cancer 2020 part 2 - advanced breast cancer: new treatments and implementation of therapies with companion diagnostics

<p>For patients with locally advanced or metastatic breast cancer, new and effective therapies such as CDK4/6 inhibitors, PARP inhibitors and a PD-L1 inhibitor have been introduced in recent years. This review presents an update on the available studies with their data. In addition, two innova...

Full description

Saved in:
Bibliographic Details
Main Authors: Lüftner, Diana (Author) , Schneeweiss, Andreas (Author) , Hartkopf, Andreas (Author) , Müller, Volkmar (Author) , Wöckel, Achim (Author) , Janni, Wolfgang (Author) , Ettl, Johannes (Author) , Belleville, Erik (Author) , Schütz, Florian (Author) , Thill, Marc (Author) , Huober, Jens (Author) , Fasching, Peter Andreas (Author) , Kolberg, Hans-Christian (Author) , Pöschke, Patrik (Author) , Welslau, Manfred (Author) , Overkamp, Friedrich (Author) , Tesch, Hans (Author) , Fehm, Tanja (Author) , Lux, Michael Patrick (Author)
Format: Article (Journal)
Language:English
Published: 21. April 2020
In: Geburtshilfe und Frauenheilkunde
Year: 2020, Volume: 80, Issue: 04, Pages: 391-398
ISSN:1438-8804
DOI:10.1055/a-1111-8775
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1055/a-1111-8775
Verlag, lizenzpflichtig, Volltext: http://www.thieme-connect.de/DOI/DOI?10.1055/a-1111-8775
Get full text
Author Notes:Diana Lüftner, Andreas Schneeweiss, Andreas D. Hartkopf, Volkmar Müller, Achim Wöckel, Wolfgang Janni, Johannes Ettl, Erik Belleville, Florian Schütz, Marc Thill, Jens Huober, Peter A. Fasching, Hans-Christian Kolberg, Patrik Pöschke, Manfred Welslau, Friedrich Overkamp, Hans Tesch, Tanja N. Fehm, Michael P. Lux
Description
Summary:<p>For patients with locally advanced or metastatic breast cancer, new and effective therapies such as CDK4/6 inhibitors, PARP inhibitors and a PD-L1 inhibitor have been introduced in recent years. This review presents an update on the available studies with their data. In addition, two innovative anti-HER2 therapies are presented (trastuzumab-deruxtecan and tucatinib) for which the results from new studies have been reported. Molecular tests offer the possibility of defining patient populations or also monitoring courses of therapy. This can help identify patients with specific characteristics in order to provide them with individually targeted therapy within the framework of studies. In a large study, the benefit of such a biomarker study was able to be described for the first time.</p>
Item Description:Gesehen am 18.06.2020
Physical Description:Online Resource
ISSN:1438-8804
DOI:10.1055/a-1111-8775

Similar Items